PHAT - Phathom Pharmaceuticals: A Clinical-Stage Company With A De-Risked Pipeline For 2020
Today, we will study why Phathom Pharmaceuticals (PHAT) is an attractive pick in 2020.
Company overview
Launched by Takeda Pharmaceuticals ([[TKPHF]]) in May 2019, Phathom Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatment options for gastrointestinal diseases. The company’s lead asset, vonoprazan, is already approved in ten countries in Asia and Latin America in indications such as reflux esophagitis, GERD, H. pylori eradication, erosive esophagitis, and peptic ulcer disease. Takeda has already completed 17 successful Phase 3 clinical trials with this drug. Phathom Pharmaceuticals has in-licensed rights